Sherlock Biosciences engineers biology to deliver products for molecular diagnostics, aiming to democratize and decentralize testing to personalize healthcare and impact global health.

Sherlock Biosciences

AMPLY Discovery leverages evolution and machine learning to discover new drugs through technology that digitizes biological diversity using next-generation sequencing.

AMPLY Discovery

CRISPR Biotech Engineering is an early-stage genome editing company that is committed to using innovative CRISPR-Cas9 technology to improve human lives.

CRISPR Biotech Engineering

Sherlock Biosciences aims to disrupt molecular diagnostics with better, faster, affordable tests.

With our unique Engineering Biology platforms, we are on the cusp of solving challenges ranging from faster pathogen detection and simpler testing for cancer to improved food safety. We envision a world where our products will enable users to make more effective decisions in any environment, whether in hospitals, industrial settings, the developing world, or at home.

Our team and founders include Engineering Biology pioneers with world-leading expertise in CRISPR and Synthetic Biology, diagnostic industry veterans, and disease-area authorities. Together, they provide an unparalleled set of capabilities that are transforming molecular diagnostics in clinical and non-clinical settings. 


Bill & Melinda Gates Foundation

Open Philanthropy Project

Northpond Ventures

Baidu Ventures

Good Ventures

Illumina Ventures

Catalio Capital Management

Novalis LifeSciences

Albany Capital

Alameda Research

We at Sherlock Biosciences are extremely passionate about WHY we do what we do!

#HealthCare4All #BreakBarriers #Innovation #SherlockBiosciences

Misconceptions about STIs are widespread, highlighting the urgent need for better education and accessible testing. At Sherlock Biosciences, we are committed to stopping the spread of STDs by developing accurate, fast, and affordable at-home diagnostic tests, ensuring everyone can take control of their sexual health. #Health #STIs #STIs #Innovation #MedicalDevice

Learn More: https://bit.ly/3LOrBS7

Your future healthcare journey begins with accurate, affordable, accessible diagnostics tests. Learn more from our CEO @[Bryan Dechairo](urn:li:person:cd1aI8c9lT). #Healthcare #DiagnosticTest #Innovation #@[Boyd Biomedical](urn:li:organization:484145)

Proud to be one of 28 institutions supporting the 2024 #MAClimateBill. To build a #CleanEnergy future, we must build a responsibly-sited grid, deploy #RenewableEnergy, electrify our transportation & #Decarbonize homes & businesses. #ClimateGoals 

➡️ Learn More: https://bit.ly/4fthy2H

At Sherlock Biosciences, we are committed to addressing the STI epidemic with low-cost, easy-to-use, and over-the-counter solutions. Our goal is to empower individuals to take control of their health through accessible STI testing. By providing rapid and accurate diagnostics, we can help reduce transmission and promote better sexual health for everyone. #SexualHealth #STIawareness #DiagnosticsInnovation
https://bit.ly/3y78ZJW

We're excited to announce our collaboration with SMART4TB to develop a swab-based point-of-care molecular test for Tuberculosis (TB). This innovative test aims to close diagnosis gaps, especially in resource-limited settings. Together, we strive for a TB-free future! #HealthcareInnovation #TBResearch #MedicalDiagnostic

Learn More: https://lnkd.in/gEdvZwzd

Metric
Company Name	Sherlock Biosciences	AMPLY Discovery	CRISPR Biotech Engineering
Symbol
MSH ID	BIO:SHERLOCK	COM:AMPLYDISCOVERY	COM:CRISPR-BTE
Market	PRIVATE	PRIVATE	PRIVATE
Sector	Healthcare & Health Services	Healthcare & Health Services	Healthcare & Health Services
Industry	Biotechnology	Biotechnology	Biotechnology
Country	US	GB	GB
Stage
Employee Count	75	7
Website	sherlock.bio	amplydiscovery.com	crispr-bte.com
LinkedIn	sherlock-biosciences
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

BIO:SHERLOCK

Sherlock Biosciences

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue